85 related articles for article (PubMed ID: 22276609)
1. Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.
Santacana M; Yeramian A; Velasco A; Bergada L; Gatius S; García V; Azueta A; Palacios J; Dolcet X; Oliva E; Matias-Guiu X
Histopathology; 2012 Feb; 60(3):460-71. PubMed ID: 22276609
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1 alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma.
Horrée N; Gort EH; van der Groep P; Heintz AP; Vooijs M; van Diest PJ
J Pathol; 2008 Jan; 214(1):38-45. PubMed ID: 17985331
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.
Pallares J; Martínez-Guitarte JL; Dolcet X; Llobet D; Rue M; Palacios J; Prat J; Matias-Guiu X
J Pathol; 2004 Dec; 204(5):569-77. PubMed ID: 15481028
[TBL] [Abstract][Full Text] [Related]
5. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
6. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
7. Protocadherin 10 inhibits cell proliferation and induces apoptosis via regulation of DEP domain containing 1 in endometrial endometrioid carcinoma.
Yang Y; Jiang Y; Jiang M; Zhang J; Yang B; She Y; Wang W; Deng Y; Ye Y
Exp Mol Pathol; 2016 Apr; 100(2):344-52. PubMed ID: 26970279
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional upregulation of HIF-1α by NF-κB/p65 and its associations with β-catenin/p300 complexes in endometrial carcinoma cells.
Yoshida T; Hashimura M; Mastumoto T; Tazo Y; Inoue H; Kuwata T; Saegusa M
Lab Invest; 2013 Nov; 93(11):1184-93. PubMed ID: 24042437
[TBL] [Abstract][Full Text] [Related]
9. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
Saegusa M; Hamano M; Kuwata T; Yoshida T; Hashimura M; Akino F; Watanabe J; Kuramoto H; Okayasu I
Cancer Sci; 2003 Jan; 94(1):103-11. PubMed ID: 12708483
[TBL] [Abstract][Full Text] [Related]
11. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract][Full Text] [Related]
14. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner.
Yeramian A; Santacana M; Sorolla A; Llobet D; Encinas M; Velasco A; Bahi N; Eritja N; Domingo M; Oliva E; Dolcet X; Matias-Guiu X
Lab Invest; 2011 Jun; 91(6):859-71. PubMed ID: 21537326
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression.
Shih HC; Shiozawa T; Miyamoto T; Kashima H; Feng YZ; Kurai M; Konishi I
Anticancer Res; 2004; 24(6):3843-50. PubMed ID: 15736420
[TBL] [Abstract][Full Text] [Related]
17. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
18. Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer.
Hashiguchi Y; Tsuda H; Bandera CA; Nishimura S; Inoue T; Kawamura N; Berkowitz RS; Mok SC
Med Oncol; 2006; 23(2):205-12. PubMed ID: 16720920
[TBL] [Abstract][Full Text] [Related]
19. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
Ozbudak IH; Karaveli S; Simsek T; Erdogan G; Pestereli E
Gynecol Oncol; 2008 Mar; 108(3):603-8. PubMed ID: 18191183
[TBL] [Abstract][Full Text] [Related]
20. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
